Bilingual Labelling for Drugs and NHPs in Canada: What Health Canada's Official Language Requirements Actually Demand

A French translation that’s grammatically correct but uses the wrong medicinal ingredient name — that’s how product submissions get flagged, even after months of preparation. Health Canada’s reviewers check bilingual compliance systematically, and the deficiencies they find aren’t usually about sloppy translation. They’re about manufacturers who don’t realize that French labelling requirements in Canada operate on two distinct legal tracks, each with its own enforcement mechanism and its own way of creating compliance gaps. Getting one right while missing the other is more common than most regulatory teams expect.

The Federal Requirement: What Section C.01.004 and the NHPR Actually Say

Under the Food and Drug Regulations (FDR), C.R.C., c. 870, Section C.01.004 establishes the baseline: every label applied to a drug for sale in Canada must appear in both English and French. This applies to inner and outer labels alike. It’s not enough to put the bilingual content only on the outer packaging and leave the immediate container label in a single language — both must carry the full required information in both official languages, regardless of size constraints.

For natural health products, Section 94 of the Natural Health Products Regulations (NHPR), SOR/2003-196, sets out an equivalent requirement. The following information must appear in both official languages on every NHP sold in Canada:

• Recommended conditions of use, including directions and route of administration
• Medicinal ingredients, their quantity or potency per dosage unit, and source organism
• Non-medicinal ingredients
• Any cautions, warnings, or contra-indications
• Storage conditions
• The product licence number (NPN or DIN-HM)

One detail that genuinely surprises manufacturers encountering Canada’s natural health products regulations for the first time: Health Canada’s bilingual requirement under the NHPR does not allow you to put the French content in a package insert while the English content appears on the label itself. Both languages must appear on the label — together, not separately.

The Consumer Packaging and Labelling Act (CPLA), R.S.C. 1985, c. C-38, administered by the Competition Bureau but coordinated with Health Canada for health products, adds one more layer: the common name and net quantity of any consumer product must appear in both official languages with equal prominence. “Equal prominence” is a defined standard, not a general principle — and its practical implications trip up a lot of packaging designers.

What “Equal Prominence” Means When You’re Actually Designing a Label

Equal prominence sounds like a simple concept until you’re staring at a label proof at 11 p.m. with a submission deadline the next morning. Here’s how it breaks down in practice.

Font height. The Food and Drug Regulations specify a minimum font height of 1.5mm for readable text on drug labels. That’s a floor, not a design target. French text typically runs 15–25% longer than equivalent English, which means if you’ve allocated space for the English version first and then try to fit the French translation into the remaining area, you’ll almost always end up compressing the French to a smaller font size to make it fit. That compression produces a deficiency. The solution is to design for the longer language first.

Typeface weight. Bold English text with regular-weight French beside it is considered unequal prominence. This comes up often with product names on principal display panels — the brand name appears heavy and dominant in English, with a lighter French equivalent alongside it. Health Canada reviewers do flag this.

Placement. English content on the principal display panel with French relegated to a side or back panel doesn’t meet the standard for required labelling elements. Both languages must appear on the same surface for every piece of mandatory information. Some manufacturers work around this with parallel columns or alternating bilingual blocks, both of which are acceptable if executed consistently.

Quebec’s Charter of the French Language: The Layer That Catches Manufacturers Off Guard

Here’s where the complexity increases significantly for any product sold in Quebec. The Charter of the French Language (commonly called Bill 101, CQLR c. C-11) imposes requirements that go beyond federal bilingual compliance. Under Bill 101, French isn’t just co-equal — it must be the predominant language on product labels for goods sold in Quebec.

The practical consequences are real:

Any text on a label in a language other than French must be accompanied by a French version that is at least as prominent in terms of font size, legibility, and visual weight. If a product name appears in English, a French equivalent must appear at minimum as prominently — and in some cases, the French must be more prominent. The Office québécois de la langue française (OQLF) actively monitors product labels through market surveillance and has authority to require corrective action from retailers and importers, not just manufacturers.

This creates a situation where a label that fully satisfies the federal FDR bilingual requirements may still be found deficient under Quebec’s provincial rules. The two regimes overlap but aren’t identical, and a significant number of compliance notices for Quebec-distributed products trace back to this gap. Companies that do their bilingual review against the federal standard only and don’t specifically assess Bill 101 compliance are running a real risk, especially as OQLF enforcement activity has increased in recent years.

Five Bilingual Labelling Deficiency Patterns We See Repeatedly

Across drug and NHP submissions, the same categories of bilingual deficiency come up consistently. These aren’t edge cases — they’re the patterns that recur most often.

Incorrect French names for medicinal ingredients. Health Canada maintains approved bilingual nomenclature for ingredients. Using a pharmacopoeial synonym, a common name from a French dictionary, or a literal translation that doesn’t match Health Canada’s approved list will get flagged during review. This is especially common with botanical ingredients, where Latin binomials are used correctly in the English portion but a non-standard French common name appears in the French portion. The Licensed Natural Health Products Database (LNHPD) is your authoritative source for approved bilingual NHP ingredient names. For drugs, the Drug Product Database (DPD) carries approved bilingual nomenclature.

Inner label omissions. Manufacturers apply bilingual labelling to the outer carton and product insert but leave the immediate container label — bottle, blister pack, vial — in English only. Section C.01.004 of the FDR doesn’t exempt inner labels based on size. If the product has an inner label, it requires bilingual content. If genuine size constraints make full bilingual labelling physically impossible on a small inner label, there’s a process for requesting an exemption, but it requires documentation and advance approval — not something to discover at submission time.

Font size compression in French text. As above — designing for English first and fitting French into the remaining space almost always produces this deficiency. It’s mechanical, predictable, and entirely avoidable if caught at the design stage.

Dosage and direction translations that alter clinical meaning. A translation can be grammatically correct and still subtly change the meaning of dosing instructions. “Take once daily with food, in the morning” can lose the timing qualifier in translation and become “take daily with food.” That’s both a bilingual deficiency and a labelling accuracy issue — reviewers flag it on both counts.

Missing bilingual content on product inserts and patient leaflets. For prescription drugs, the patient medication information (PMI) sections that are patient-facing must appear in both official languages. Getting the prescribing information right bilingually but leaving the PMI in English only is a persistent miss. For over-the-counter drugs and NHPs, any accompanying insert that contains required labelling information — warnings, directions, storage — must be bilingual if the label itself is bilingual.

Building Bilingual Compliance Into Your Process Before Submission

The most effective thing you can do is treat bilingual compliance as a design constraint from day one, not a review step you add before submission. A few approaches that consistently produce cleaner results:

Start with the French. Size your label real estate for the French text, then fit the English into the same space. You’ll almost never have font-size issues.

Use Health Canada’s databases, not translation tools. The LNHPD and DPD are your authoritative sources for approved bilingual ingredient names. General-purpose translation software, even high-quality tools, won’t consistently match Health Canada’s approved nomenclature.

Run a separate Quebec compliance review. If your product will be distributed nationally in Canada — which for most manufacturers means Quebec distribution — assess the label specifically against Bill 101 criteria, not just the federal standard. These are two separate checklists.

Document your bilingual review. Health Canada reviewers want to see that you’ve verified bilingual compliance systematically, not just that the label looks bilingual. A label review record that maps each required element, its English content, its French equivalent, and the source for the French translation is both a quality practice and the kind of documentation a Canada GMP inspector or Health Canada reviewer expects to see in your regulatory package.

Labelling deficiencies surface early in the review process and add months to your timeline when they do. Most of them are predictable and preventable. The manufacturers who move through Health Canada review without labelling-related delays are almost always the ones who treated bilingual compliance as a first-principles design requirement, not an afterthought.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025 Laboratory Testing for Canadian Pharmaceutical Submissions — Qalitex Laboratories provides accredited analytical testing in support of Health Canada drug and NHP submissions, including ingredient identity, potency, and contaminant testing.
• EU Cosmetic Labelling Under Regulation 1223/2009 — Care Europe covers the multilingual labelling requirements that apply to cosmetic products entering EU markets, including French-language obligations across member states.